Work

Abstract CT267: First results of ART0380 (an ATR kinase inhibitor) with low dose irinotecan in advanced or metastatic solid tumors

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct267

Authors: Susanna Ulahannan, Jason T. Henry, Kathleen N. Moore, Gerald S. Falchook, Meredith S. Pelster, Elisa Fontana, Bryony Harrop, Nicola Little, Helen Millward, Amelia Fielding, Sara Busacca, Emre Karakoc, Suraj Menon, Sarah V. Holt, Niall Martin, Graeme C. Smith, Desiree Headley, Ian C. Smith, Bert H. O'Neil, Babar Bashir

Institutions: OU Health Stephenson Cancer Center, University of Oklahoma, HealthONE, Sarah Cannon, Sarah Cannon Research Institute, Artios Pharma Limited (United Kingdom), Community Health Network, Thomas Jefferson University, Sidney Kimmel Cancer Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409821595

Cites:

Cited by: 4

Related to: 10